SEC Form 4 · accession 0001209191-15-010443
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Feb 5, 2015
Accepted (ET)
Feb 6, 2015 · 5:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 5, 2015 | M | 1,688 | $45.11 | A | 25,750 | D | |
| Common StockF2,F3 | Feb 5, 2015 | S | 400 | $108.81 | D | 25,350 | D | |
| Common StockF3,F4 | Feb 5, 2015 | S | 900 | $109.74 | D | 24,450 | D | |
| Common StockF3,F5 | Feb 5, 2015 | S | 388 | $110.76 | D | 24,062 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F6 | $45.11 | Feb 5, 2015 | M | 1,688 | D | — | Feb 4, 2023 | Common Stock | 1,688 | 13,500 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $108.81 (range $108.27 to $109.10).
- F3Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $109.74 (range $109.45 to $110.13).
- F5Open market sales reported on this line occurred at a weighted average price of $110.76 (range $110.50 to $111.03).
- F6The option vests in 16 quarterly installments from 02/05/2013.